Gov’t to streamline approval of traditional Chinese medicines for oral use

It will apply to traditional pCms used in Hong Kong for more than 15 years.

The National Medical Products Administration (NMPA) said it would streamline the approval process for Hong Kong-registered traditional proprietary Chinese medicines (pCms) for oral use to be registered on the mainland.

It will apply to traditional pCms for oral use which have been registered with the Chinese Medicine Council of Hong Kong and used in Hong Kong for more than 15 years. 

“Since its implementation, 13 Hong Kong-registered pCms have been approved for sale on the Mainland through streamlined procedures,” Secretary for Health, Professor Lo Chung-mau, said.

To assist Hong Kong Chinese medicine traders, the Chinese Medicine Development Fund of the Health Bureau launched the Guangdong-Hong Kong-Macao Greater Bay Area Proprietary Chinese Medicine Industry Development Support Scheme in February 2024.

The scheme aims to provide financial support to Hong Kong pCm manufacturers or wholesalers regarding registration applications and support them in making applications on the Mainland for eligible pCms.